Abaloparatide — EU research guide.
Abaloparatide is a synthetic 34-amino-acid analogue of PTHrP (parathyroid hormone-related protein) approved in the US as Tymlos for osteoporosis. It selectively activates PTH1R in the RG conformation, producing more anabolic bone effects than teriparatide.
What is Abaloparatide?
Abaloparatide selectively binds the RG (high-affinity) conformation of PTH1R rather than the RO conformation, producing more transient cAMP signalling and greater anabolic (bone-forming) versus catabolic (bone-resorbing) effects than teriparatide (PTH 1-34). It was approved by FDA in 2017 as Tymlos for postmenopausal osteoporosis with severe fracture risk.
What does the research show?
The ACTIVE trial showed superior vertebral fracture risk reduction versus placebo and non-inferior hip fracture reduction versus teriparatide. The anabolic window — the period of net bone formation — appears wider with abaloparatide due to its receptor binding selectivity. Research interest focuses on bone biology, PTH1R pharmacology and comparative anabolic mechanisms.
EU legal status
FDA-approved in the US (Tymlos) but not EMA-approved in the EU as of mid-2026. Research-grade abaloparatide is available from EU vendors for bone biology research. Not for human use without prescription in jurisdictions where it is approved.
Molecular information
Pharmacokinetics
Abaloparatide across EU suppliers
COA-verified EU vendors · Updated monthly